¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor control dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
¿µ¹® benign tumor ÇÑ±Û ¾ç¼ºÁ¾¾ç
¼³¸í   
  ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, Ä§À±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇϴ Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀΠ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í Çصµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇϴ ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡Çϴ ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇϴ ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸À̴ Á¾¾çµµ ÀÖ´Ù.
¿µ¹® Wilms' tumor ÇÑ±Û Àª¸§ÁîÁ¾¾ç
¼³¸í   
  ÄáÆÏ¿¡¼­ ¹ß»ýÇϴ ¾Ç¼ºÁ¾¾çÀ¸·Î ¼Ò¾Æ¿¡¼­ ÀÚÁÖ ¹ß»ýÇÑ´Ù. ÈçÈ÷ ¼Ò¾Æ¿¡¼­ º¹ºÎ³»Á¾¾çÀ» ¹ß°ß½Ã Áß¾Ó¼±À» ³Ñ¾î¼­¸é ½Å°æ¸ð¼¼Æ÷Á¾À̰í, Áß¾Ó¼±À» ³ÑÁö ¾ÊÀ¸¸é Àª¸§ÁîÁ¾¾çÀ» ÀǽÉÇÒ ¸¸Å­ Áß¿äÇϰí ÈçÇÑ Á¾¾çÀÌ´Ù. ´ë°³ Áõ»óÀº ¾ø´Â ÆíÀ̸ç, ÁַΠ¾Æ±âÀÇ ¸ñ¿åÀ» ½ÃÄÑÁÖ´Ù°¡ ¿ì¿¬È÷ ¹ß°ßµÈ º¹ºÎ³»Á¾±« ¶§¹®¿¡ º´¿øÀ» Ã£°Ô µÈ´Ù. Áø´Ü½Ã ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µÀ¸·Î ÁÖÀ§ÀÇ ÀüÀ̰¡ ¾ø´ÂÁö¸¦ È®ÀÎÇØ¾ß Çϸç, ÀüÀ̰¡ ¾øÀ¸¸é Ç×¾ÏÈ­Çпä¹ý, ¹æ»ç¼±Ä¡·á¿ä¹ý, ±×¸®°í ¼ö¼ú¿ä¹ýÀÇ º´ÇÕ¿ä¹ý¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù. 
¿µ¹® mucinous tumor ÇÑ±Û Á¡¾×Á¾¾ç
¼³¸í   
  Á¡¾×À¸·Î ±¸¼ºµÈ Á¾¾çÀ» ¸»Çϴµ¥ ÁַΠ¿©¼ºÀÇ ³­¼Ò¿¡¼­ ¹ß»ýÇϴ ³¶¼º(¹°ÁָӴϰ°Àº Á¾¾çÀ» ¸»ÇÔ) Á¾¾ç¿¡¼­ ¸¹ÀÌ º¼ ¼ö ÀÖ´Ù.
¿µ¹® tumor ÇÑ±Û Á¾¾ç
¼³¸í   
  Á¶ÀýÇÒ ¼ö ¾øÀÌ °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë. ½Å»ý¹°.
  
  (1) ºÐ·ù
  
    A. Ä§À±°ú ÀüÀÌÀÇ À¯¹«¿¡ µû¶ó
  
      i)¾ç¼ºÁ¾¾ç: Ä§À±°ú ÀüÀ̰¡ ¾ø°í ¿ªÇü¼ºÀÌ ³·Àº ¼¼Æ÷·Î ±¸¼ºµÊ. ´ë°³ Ä¡·á¿¡ ¹ÝÀÀÀÌ ³ô°í, »ý¸í¿¡ Å©°Ô ÁöÀåÀÌ ¾øÀ¸¸ç, Àç¹ßÇϴ °æ¿ìµµ Àû´Ù. Áõ»óÀº ´ÜÁö ÁÖÀ§Á¶Á÷¿¡ ´ëÇÑ ¾Ð¹ÚÁ¤µµÀÌ´Ù.
  
      ii)¾Ç¼ºÁ¾¾ç: Ä§À±°ú ÀüÀ̰¡ ÀÖ°í ÅðÈ­µµ°¡ ³ôÀº ¼¼Æ÷·Î ±¸¼ºµÊ. ±â¿ø¼¼Æ÷°¡ »óÇÇÁ¶Á÷ÀÏ °æ¿ì ¾ÏÁ¾, ºñ»óÇǼºÀÏ °æ¿ì À°Á¾À¸·Î ³ª´©±âµµ ÇÑ´Ù. Ä¡·á¿¡ Àß ¹ÝÀÀÇÏÁö ¾Ê°í, Àç¹ßÀ» Àß Çϸç, »ýÁ¸À²ÀÌ ³·´Ù. ÈçÈ÷ ¸»Çϴ ¡°¾Ï¡±À» ÀǹÌÇÑ´Ù.
  
    B. Á¶Á÷ÇÐÀû Æ¯Â¡¿¡ µû¶ó »ùÁ¾, Áö¹æÁ¾, ±ÙÁ¾ µîÀ¸·Î ³ª´©±âµµ ÇÑ´Ù.
  
  (2) º´¸®Á¶Á÷ÇÐÀû Æ¯Â¡
  
    A. À°¾ÈÀû ¼Ò°ß
  
  µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ Çϰí Á¤»óÁ¶Á÷¿¡ ½º¸çµéµíÀÌ ÆÇ»ó±¸Á¶¸¦ ÀÌ·ç±âµµ Çϴ µî ´Ù¾çÇÑ ÇüŸ¦ º¸ÀδÙ. ¾ç¼ºÀÇ °æ¿ì ÇǸ·À» °¡Áø °æ¿ì°¡ ¸¹°í ¾Ç¼ºÀÇ °æ¿ì ¾ø´Â °æ¿ì°¡ ¸¹´Ù.
  
  À°¾È¼Ò°ß¿¡ µû¶ó ´ÙÀ½°ú °°ÀÌ ³ª´«´Ù. ³¶¼º, À¶±â¼º, ±«»ç¼º, Æú¸³¸ð¾ç, ±Ë¾çÇü µîÀÌ ÀÖ´Ù. ¶Ç´Â ¼¼Æ÷ÀÇ Å©±â¿Í ¸ð¾çÀÌ ºñÁ¤»óÀûÀΠÇüÅ·Πº¯È­ÇÑ´Ù. ÇÙÀÇ ±Ø¼ºÀÌ »ç¶óÁö°í ÇÙÀÇ ¿°»ö¼ºÀ̠£¾îÁø´Ù. ¼¼Æ÷ÁúÀÇ ¿°»ö¼ºµµ º¯È­Çϸ砼¼Æ÷µé°£ÀÇ ¼¼Æ÷ÁֱⰡ ¸Å¿ì ´Ù¾çÇØÁ® ¸¹Àº ¼¼Æ÷ºÐ¿­À» º¸ÀδÙ. ÀÌ·¯ÇÑ ÀÏ·ÃÀÇ º¯È­¸¦ ¿ªÇü¼ºÀ̶ó ÇÑ´Ù. ¿ªÇü¼ºÀÇ Á¤µµ¿¡ µû¶ó Á¶Á÷ÇÐÀû µî±ÞÀ» ³ª´«´Ù. ¶ÇÇÑ °¢ Á¾¾ç¿¡ µû¶ó °¢±â ´Ù¸¥ º´¸®Á¶Á÷ÇÐÀû ¸íĪÀ» ºÙÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • odontogenic tumor
    Ä¡¿ø¼ºÁ¾¾ç
  • organoid tumor
    Àå±â¸ð¾çÁ¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • polypoid tumor
    Æú¸³¸ð¾çÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • retroperitoneal tumor
    Èĺ¹¸·Á¾¾ç, ¹è¸·µÚÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
  • solid-cystic tumor
    °íÇü³¶¼ºÁ¾¾ç
  • spinal cord tumor
    ô¼öÁ¾¾ç
  • steroid cell tumor
    ½ºÅ×·ÎÀ̵弼Æ÷Á¾¾ç
  • stromal tumor
    °£ÁúÁ¾¾ç, ¹öÆÀÁúÁ¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¾ÆÅ¿Á¾¾ç, Ä¡¿øÁ¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mixed germ cell tumor
    È¥ÇÕ¹è¾Æ¼¼Æ÷Á¾¾ç
  • tumor marker
    Á¾¾çÇ¥ÁöÀÚ
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¿øÁ¾¾ç, Ä¡¾ÆÅ¿Á¾¾ç
  • organoid tumor
    (¢¡teratoma) ±âÇüÁ¾
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phantom tumor
    ȯ°¢Á¾¾ç, ȯ»óÁ¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • polypoid tumor
    Æú¸³Á¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç
  • retroperitoneal tumor
    ¹è¸·µÚÁ¾¾ç, º¹¸·µÚÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MED=£¾minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MTD=> maximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=£¾maximum tolerance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=ÊÝmaximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • STD= standard test dose
    Ç¥ÁؽÃÇè·®.
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • communicable disease control
    Àü¿°º´°ü¸®(ÊÙË´Ëö), Àü¿°º´¿¹¹æ.
  • conception control
    ¼öÅÂÁ¶Àý(¡­ðàï½).
  • control
    ´ëÁ¶, Á¶Àý
  • control
    ´ëÁ¶
  • control
    ´ëÁ¶(¾à).
  • control
    ´ëÁ¶(ËÀÌ¡), Á¶Àý(Ì¡Ëø), Á¦¾î(Ì¡Ëâ), °ü¸®(Ë´Ëö), ±ÔÁ¦(˻̡), ¹æÁ¦( ËÑÌ¡) ÊÙÀ¯Çع°ÁúÀÇÊÙ.
  • control equipment
    Á¦¾îÀåÄ¡(Ì¡ËâËö̬).
  • control equipment
    Á¦¾îÀåÄ¡(ð¤åÙíûöÇ).
  • control equipment
    Á¦¾îÀåÄ¡(Á¦¾îÀåÄ¡).
  • control experiment
    ´ëÁ¶½ÇÇè(ÓßðÎãùúÐ).
  • control experiment
    ´ëÁ¶½ÇÇè(ËÀÌ¡ËàÌ´).
  • control gene
    Á¦¾îÀ¯ÀüÀÚ(ð¤åÙë¶îîí­).
  • control group
    ´ëÁ¶±º(ÓßðÎÏÛ)
  • control group
    ´ëÁ¶±º(ËÀ̡˴).
  • control handle
    Á¶Àý¹½__
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • absorbed dose
    Èí¼ö·® (ýåâ¥Õá)
  • air dose
    ´ë±â¼±·®(ÓÞѨàÊÕá)
  • booster dose
    ºÎ½ºÅÍ ·®(Õá)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • exposure dose
    ³ëÃâ·®(ÖÚõóÕá)
  • fractionated dose
    ºÐÇÒ·®(ÝÂùÜÕá)
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
  • maximum permissible dose
    ÃÖ´ëÇã¿ë·®(õÌÓÞúÉé»Õá)
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
  • median hemolytic dose
    Á¤Áß ¿ëÇü·®(ïáñééÁúìÕá)
  • median immunizing dose
    Á¤Áß ¸é¿ª·®(ïáñéØóæµÕá)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carotid body tumor
    °æµ¿¸Æ¼ÒüÁ¾¾ç
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
  • glomus jugulare tumor
    °æÁ¤¸Æ±¸Á¾¾ç
  • glomus tumor
    »ç±¸Á¾¾ç, ±Û·Î¹«½ºÁ¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸¼ºÁ¾¾ç
  • hormone producing tumor
    È£¸£¸ó»ý»êÁ¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mediastinal tumor
    Á¾°ÝÁ¾¾ç
  • mesenteric tumor
    Àå°£¸·Á¾¾ç
  • metastatic tumor
    ÀüÀ̼ºÁ¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mucoepidermoid tumor
    Á¡¾×Ç¥ÇǾçÁ¾¾ç
  • mucous tumor
    Á¡¾×Á¾
  • nasopharyngeal tumor
    ºñÀεÎÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
BT base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
TNM primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas...
BCM B-cell maturation; birth control medication; blood-clotting mechanism effects; body cell mass; body ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DMF Dose Modifying Factor
DRF Dose Reduction Factor
DAP Dose area product
DLT Dose limiting toxicities
DLT Dose limiting toxicity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • air dose
    °øÁß ¼±·®, °ø±âÁß ¼±·®
    ´Ù¸¥ ¹°Ã¼¿¡ ÀÇÇÑ »ê¶õ¼±À» Á¦¿ÜÇÑ °ø±â ÁßÀÇ ¼±·®. ÀϹÝÀûÀ¸·Î ¹°Ã¼ÀÇ Ç¥¸é¿¡ À־µµ, ¶Ç´Â »ýü Á¶Á÷ ³»ÀÇ ÀÏ Á¡¿¡¼­ÀÇ ¼±·®À¸·Î¼­µµ ¸ðµç »ê¶õ¼±ÀÇ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ °øÁß ¼±·®º¸´Ù ¸¹¾ÆÁø´Ù.
  • average dose
    Æò±Õ ¿ë·®, Æò±Õ Á¶»ç·®
  • average maintenance dose
    µð±âÅ»¸®½º Æò±Õ À¯Áö·®
  • basal dose
    ±âº» ¼±·®
  • booster dose
    Ãß°¡ Á¢Á¾·®
  • committed effective dose equivalent
    ¿¹Å¹ À¯È¿ ¼±·® ´ç·®
  • cumulative absorbed dose
    ´©Àû ¼±·®, ´©Àû Èí¼ö¼±·®
  • cumulative dose
    ÁýÀû ¼±·®, ´©Àû Á¶»ç·®, ´©Àû ¿ë·®, Ãàô ¿ë·®
  • curative dose
    ġȿ·®
  • daily dose
    ÀÏÀÏ·®, ÀϿ뷮
  • dose calculation
    ¼±·® °è»ê
  • dose commitment
    ¼±·® ¿¹Å¹
  • dose costraint
    ¼±·® ±¸¼ÓÄ¡
  • dose equivalent
    ¼±·® ´ç·®
    ¹æ»ç¼±ÀÇ ½ÇÈ¿Àû ¼±·®. ¹æ»ç¼± ¹æÈ£ ÀÔÀå¿¡¼­ Á¾·ù³ª ¿¡³ÊÁö°¡ ´Ù¸¥ ¹æ»ç¼±ÀÌ »ýü¿¡ ¹ÌÄ¡´Â È¿°ú¿¡ ÁÖ¸ñÇÏ¿© ±Ù³â¿¡ ¿Í¼­ Á¤ÀǵǾú´Ù. ´ÜÀ§´Â remÀÌ´Ù.
  • dose limit
    ¼±·® Çѵµ, ¼±·® Á¦ÇÑ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
dose-effect curve This is a graph drawn to show the relationship between the dose of a drug or other chemical and the magnitude of the graded effect that it produces.
(09 Oct 1997)
dose-escalation A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose fractionation Adminstration of the total dose of radiation (radiation dosage) in parts, at timed intervals.
(12 Dec 1998)
dose intensity In chemotherapy, the total amount of drug delivered in a one-week period. Can be given all at once or over a period of several days.
(16 Dec 1997)
dose-ranging A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose-response curve This is a graph to show the relation between the dose of a drug or other chemical and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(09 Oct 1997)
dose-response relationship Relationship in which a change in the amount, intensity, or duration of exposure is associated with a change in risk of a specified outcome.
(05 Mar 2000)
dose-response relationship, drug The relationship between the dose of an administered drug and the response of the organism to the drug.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
dose-response relationship, radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
(12 Dec 1998)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
initial dose A comparatively large dose given at the beginning of treatment to get the patient under the influence of the drug.
Synonym: loading dose.
(05 Mar 2000)
integral dose The total energy absorbed by the body, the product of the mass of tissue irradiated and the absorbed dose; unit, the gram rad.
(05 Mar 2000)
optimum dose The dose of a drug or radiation that will produce the desired effect with minimum likelihood of undesirable symptoms.
(05 Mar 2000)
therapeutic dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • control tower
    (°øÇ×ÀÇ)°üÁ¦Å¾
  • damage control
    ÀÀ±Þ ÇÇÇØ ´ëÃ¥;ÇÇÇØ ´ëÃ¥¹Ý
  • dual control
    ÀÌÁß °üÇÒ;¾ç±¹ °øµ¿ ÅëÄ¡;(°ø)ÀÌÁß Á¶Á¾ ÀåÄ¡
  • exchange control
    ȯ°ü¸®
  • fingertip control
    ¹öư Á¶Á¾(ÀåÄ¡)
  • fire control
    »ç°ÝÁöÈÖ
  • fire control radar
    È­±â °üÁ¦ ·¹ÀÌ´õ
  • flight control
    °üÁ¦¼Ò
  • flood control
    Ä¡¼ö
  • food control
    ½Ä·® °ü¸®(ºñ»ó½ÃÀÇ)
  • gain control
    (ÀüÀÚ)(¼ö½Å±â,Á߯ø±âÀÇ)À̵æ Á¦¾î
  • ground control
    (ºñÇàÀåÀÇ)Áö»ó °üÁ¦(°ü)
  • light control
    µîÈ­ °üÁ¦
  • mission control
    (Áö»óÀÇ) ¿ìÁÖ ºñÇà °üÁ¦ ¼¾ÅÍ
  • numerical control
    (Àü»ê)¼öÄ¡Á¦¾î(µðÁöÅ» °è»ê±â¿¡ ÀÇÇÑ °øÀÛ ±â°èÀÇ Á¦¾î)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á